Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021037013 - NOVEL APPLICATION OF PHENOTHIAZINES OR COMPOUND HAVING SIMILAR STRUCTURE IN PHARMACEUTICS

Publication Number WO/2021/037013
Publication Date 04.03.2021
International Application No. PCT/CN2020/110998
International Filing Date 25.08.2020
IPC
A61K 31/5415 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
5415ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 39/39 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 31/5415
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
5415ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 广州威溶特医药科技有限公司 GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 陈良 CHEN, Liang
  • 范真真 FAN, Zhenzhen
  • 贺嵩敏 HE, Songmin
  • 陈婕思 CHEN, Jiesi
  • 桑德尔马克斯 SANDER, Max
  • 龚守芳 GONG, Shoufang
  • 杨晓志 YANG, Xiaozhi
  • 林子青 LIN, Ziqing
Agents
  • 广州文冠倪律知识产权代理事务所(普通合伙) WINGUAN PATENT AND TRADEMARK ATTORNEYS
Priority Data
201910792478.526.08.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) NOVEL APPLICATION OF PHENOTHIAZINES OR COMPOUND HAVING SIMILAR STRUCTURE IN PHARMACEUTICS
(FR) NOUVELLE APPLICATION DE PHÉNOTHIAZINES OU D'UN COMPOSÉ AYANT UNE STRUCTURE SIMILAIRE DANS LE DOMAINE PHARMACEUTIQUE
(ZH) 吩噻嗪类或其类似结构的化合物在制药中的新应用
Abstract
(EN)
A novel application of a phenothiazine compound in pharmaceutics, the phenothiazine compound being selected from among a compound represented by formula (I), a hydrate, a solvate or a reduced form thereof. Specifically, the application is an application in the preparation of a PD-1 signal transduction inhibitor. The phenothiazine compound may inhibit the function of PD-1 and block the signal conduction of PD-1, so that the compound may be used as a PD-1 signal transduction inhibitor. In in vitro experiments, it was found that said type of compound can restore the function of immune cells inhibited by PD-1, thereby improving the function of immune cells, such as CTL, of secreting cytokines and killing target cells, thus improving the immune function of the body and effectively treating tumors.
(FR)
L'invention concerne une nouvelle application d'un composé phénothiazine dans le domaine pharmaceutique, le composé phénothiazine étant choisi parmi un composé représenté par la formule (I), un hydrate, un solvate ou une forme réduite de ce dernier. Plus précisément, l'application est une application dans la préparation d'un inhibiteur de transduction de signal PD-1. Le composé phénothiazine peut inhiber la fonction de PD-1 et bloquer la conduction de signal de PD-1, de sorte que le composé peut être utilisé en tant qu'inhibiteur de la transduction de signal PD-1. Dans des expériences in vitro, il a été découvert que ledit type de composé peut restaurer la fonction de cellules immunitaires inhibées par PD-1, ce qui permet d'améliorer la fonction de cellules immunitaires, telles que les CTL, de sécréter des cytokines et de tuer des cellules cibles, ce qui permet d'améliorer la fonction immunitaire du corps et de traiter efficacement des tumeurs.
(ZH)
吩噻嗪类化合物在制药中的新应用,其中所述吩噻嗪类化合物选自式(I)所示的化合物、其水合物、溶剂化物或其还原型形式,具体为在制备PD-1信号传导抑制剂中的应用。所述的吩噻嗪类化合物能够抑制PD-1的功能,使PD-1的信号传导受阻,从而可以作为PD-1信号传导抑制剂。在体外实验中发现,该类化合物可以恢复被PD-1抑制的免疫细胞的功能,从而提高CTL等免疫细胞分泌细胞因子和杀伤靶细胞的功能,从而可以提高机体的免疫功能,并且可以有效治疗肿瘤。
Also published as
Latest bibliographic data on file with the International Bureau